Rise Therapeutics, a biotechnology company in the clinical stage, has successfully enrolled its initial participant in the Phase 1 clinical trial for R-2487, a prospective treatment for rheumatoid arthritis.

Gary Fanger, Rise Therapeutics' President and CEO, highlighted the significance of this milestone for both the company and individuals grappling with rheumatoid arthritis, stating, "This accomplishment underscores our commitment to providing groundbreaking medications to the clinical community."

Rheumatoid arthritis is a chronic inflammatory disorder affecting approximately 0.24% of the global population, with about 1% of the U.S. population experiencing it. The prevalence varies based on geographical location and gender, with women being three times more susceptible than men. The condition targets patients' synovial joints, leading to disability in about half of those affected over the course of the disease.

The Phase I clinical trial for rheumatoid arthritis (NCT05961592) is a pivotal step, being the first-in-human trial aimed at assessing the safety, pharmacodynamics, and clinical efficacy of R-2487 in patients with rheumatoid arthritis. The study, conducted at multiple U.S. sites, involves single and repeat doses of R-2487, with the goal of intervening in the progression of rheumatoid arthritis before resorting to traditional infused biologics therapy. The trial aims to enroll up to 36 participants, with clinical activity evaluated based on improvements in disease severity and various key biomarker and pharmacodynamic assessments.

R-2487, a synthetic biology-based immunotherapy, is designed to address autoimmune diseases. Its mechanism of action involves inducing bystander tolerance through the evolution of T regulatory (Treg) cells, effectively resetting Treg deficiencies to reduce inflammatory cytokines contributing to autoimmune diseases. R-2487 utilizes Rise Therapeutics' proprietary oral biologics drug delivery platform, emphasizing a 'one drug, one target' approach. This, combined with a deep understanding of immune mechanisms, aims to streamline clinical trial endpoints for increased efficiency and faster outcomes.

 

Source: prnewswire.com

Report Abuse